CN113797317B - Composition, and preparation method and application thereof - Google Patents
Composition, and preparation method and application thereof Download PDFInfo
- Publication number
- CN113797317B CN113797317B CN202111251289.0A CN202111251289A CN113797317B CN 113797317 B CN113797317 B CN 113797317B CN 202111251289 A CN202111251289 A CN 202111251289A CN 113797317 B CN113797317 B CN 113797317B
- Authority
- CN
- China
- Prior art keywords
- composition
- interferon
- ascorbic acid
- interferon alpha
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title abstract description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 78
- 102000014150 Interferons Human genes 0.000 claims abstract description 60
- 108010050904 Interferons Proteins 0.000 claims abstract description 60
- 229940079322 interferon Drugs 0.000 claims abstract description 59
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 39
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 39
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 39
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 46
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 42
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 claims 1
- 239000011550 stock solution Substances 0.000 abstract description 22
- 239000004094 surface-active agent Substances 0.000 abstract description 19
- 230000009286 beneficial effect Effects 0.000 abstract description 11
- 239000000337 buffer salt Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 23
- 235000016496 Panda oleosa Nutrition 0.000 description 18
- 240000000220 Panda oleosa Species 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 239000007853 buffer solution Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 6
- 235000019799 monosodium phosphate Nutrition 0.000 description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 6
- 230000001133 acceleration Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108091006006 PEGylated Proteins Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 108010002492 human interferon alfa-1b Proteins 0.000 description 2
- 102000000707 human interferon alfa-1b Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 102100039734 Interferon alpha-10 Human genes 0.000 description 1
- 101710127454 Interferon alpha-3 Proteins 0.000 description 1
- 102100036532 Interferon alpha-8 Human genes 0.000 description 1
- 101710106111 Interferon alpha-C Proteins 0.000 description 1
- 102100026688 Interferon epsilon Human genes 0.000 description 1
- 101710147309 Interferon epsilon Proteins 0.000 description 1
- 102100022469 Interferon kappa Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010080375 interferon kappa Proteins 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 108010047126 interferon-alpha 8 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a composition for preserving an interferon stock solution, a preparation method and application thereof, and belongs to the field of biological medicine. The composition comprises an interferon, L-ascorbic acid, a buffer salt and optionally a surfactant. The composition has better stability, prolonged storage life and is beneficial to industrialized production.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to a composition, a preparation method and application thereof.
Background
Human Interferon (IFN) is a cytokine protein drug produced by activated fibroblasts and certain epithelial cells, and has antiviral infection, antitumor and strong immunoregulatory effects. Most of the interferons have the disadvantages of short half-life and strong immunogenicity in application.
The use of propylene glycol, amino acids (glycine, alanine) or human serum albumin as a protective agent has been described in the literature to improve the stability of interferon stock solutions during processing and storage, but the applicant has found during the course of implementation that the protective agents for high-concentration interferon stock solutions employed in the prior art have the following problems: propylene glycol is haemolytic, there is a risk of injection, the cost of amino acids (glycine, alanine) or human serum albumin is high, new impurities may be introduced, or detection may be affected.
Thus, there remains a need for a safe, environmentally friendly, low cost, stable interferon composition.
Disclosure of Invention
In order to solve the problems, the invention provides the following technical scheme.
In a first aspect, the present invention provides a composition of an interferon stock.
A composition comprising an interferon, L-ascorbic acid and a buffer salt. The invention adopts L-ascorbic acid, is beneficial to improving the chemical stability of interferon, avoids the reduction of the specific activity of the interferon and the increase of related proteins, can obviously prolong the freezing time of the composition, brings convenience to industrial production management and reduces the outdated loss of stock solution.
The composition may also include a surfactant. The surfactant is beneficial to reducing activity loss caused by adsorption and aggregation of a gas-liquid interface when the interferon is frozen.
The interferon may comprise recombinant interferon or interferon prepared by other methods.
The interferon may comprise an interferon selected from a human or an animal. In some embodiments, the interferon comprises at least one of interferon alpha, interferon beta, interferon omega, interferon kappa, interferon lambda, interferon epsilon, or interferon gamma. In some embodiments, the interferon comprises at least one selected from human interferon alpha, human interferon beta, or human interferon gamma. In some embodiments, the interferon comprises a member selected from interferon alpha 1, interferon alpha 2, interferon alpha 3, interferon alpha a, interferon alpha B, or interferon alpha C. In some embodiments, the interferon comprises a polypeptide selected from human interferon alpha 1a, human interferon alpha 1b, human interferon alpha 2a, and human interferon alpha 2b. In some embodiments, the interferon comprises a human interferon alpha 1a selected from the group consisting of a pegylated or fusion protein modified human interferon alpha 1b, a pegylated or fusion protein modified human interferon alpha 2a, and a pegylated or fusion protein modified human interferon alpha 2b. In some embodiments, the interferon is a kana-resistant human interferon. In some embodiments, the interferon is a kana-resistant human interferon alpha 2b.
The purity of the L-ascorbic acid can be more than or equal to 90 percent. In some embodiments, the purity of the L-ascorbic acid is greater than or equal to 95%. In some embodiments, the purity of the L-ascorbic acid is greater than or equal to 98%. The higher the purity of the L-ascorbic acid, the more advantageous is the improvement of the specific activity of the interferon in the composition.
The composition may further comprise water.
The buffer salt may include at least one selected from phosphate, citrate, or acetate.
The phosphate may include at least one selected from potassium dihydrogen phosphate, potassium hydrogen phosphate, sodium dihydrogen phosphate, or sodium hydrogen phosphate.
The citrate may include at least one selected from citric acid, potassium citrate, or sodium citrate salt.
The acetate may include at least one selected from acetic acid, ammonium acetate, sodium acetate, or potassium acetate.
The surfactant may include at least one selected from tween 80, tween 20, poloxamer P188. In some embodiments, the surfactant is tween 80.
The L-ascorbic acid may be present in an amount of 1mmol/L to 5mmol/L based on the total volume of the composition. In some embodiments, the L-ascorbic acid is present in an amount of 1.5mmol/L to 5mmol/L based on the total volume of the composition. In some embodiments, the L-ascorbic acid is present in an amount of 3mmol/L to 5mmol/L based on the total volume of the composition. In some embodiments, the L-ascorbic acid is present in an amount of 4mmol/L to 5mmol/L based on the total volume of the composition.
The buffer salt may be present in a concentration of 5mmol/L to 50mmol/L based on the total volume of the composition. In some embodiments, the buffer salt is present at a concentration of 5mmol/L to 40mmol/L based on the total volume of the composition. In some embodiments, the buffer salt is present at a concentration of 5mmol/L to 30mmol/L based on the total volume of the composition. In some embodiments, the buffer salt is present at a concentration of 5mmol/L to 20mmol/L based on the total volume of the composition. In some embodiments, the buffer salt is present at a concentration of 5mmol/L to 15mmol/L based on the total volume of the composition. In some embodiments, the buffer salt is present at a concentration of 8mmol/L to 12mmol/L based on the total volume of the composition.
The pH of the composition may be from 4.0 to 7.0. In some embodiments, the pH of the composition is from 5.0 to 7.0. In some embodiments, the pH of the composition is from 6.0 to 7.0.
The surfactant may be present in an amount of 0.001wt% to 0.05wt% based on the total mass of the composition. In some embodiments, the surfactant is present in an amount of 0.01wt% to 0.05wt% based on the total mass of the composition. In some embodiments, the surfactant is present in an amount of 0.02wt% to 0.05wt% based on the total mass of the composition.
The interferon may be present in an amount of 0.1mg/mL to 3.0mg/mL based on the total volume of the composition. In some embodiments, the interferon is present in an amount of 1.0mg/mL to 3.0mg/mL based on the total volume of the composition. In some embodiments, the interferon is present in an amount of 0.2mg/mL to 2.5mg/mL based on the total volume of the composition. In some embodiments, the interferon is present in an amount of 0.5mg/mL to 2mg/mL based on the total volume of the composition. In some embodiments, the interferon is present in an amount of 0.5mg/mL to 1.5mg/mL based on the total volume of the composition.
The composition may not comprise propylene glycol, amino acids (glycine, alanine) or human serum albumin as protective agents.
In a second aspect, the present invention provides a method of preparing the composition of the first aspect.
A method of preparing the composition of the first aspect, comprising: dissolving buffer salt, L-ascorbic acid and optional surfactant in water, mixing with interferon, sterilizing, and filtering.
In some embodiments, a method of preparing the composition of the first aspect comprises: dissolving buffer salt, L-ascorbic acid and optional surfactant in water, mixing with interferon, sterilizing, filtering, packaging, and filling nitrogen into the headspace.
In a third aspect, the present invention provides the use of a composition according to the first aspect.
Use of a composition according to the first aspect for the preparation of a pharmaceutical formulation.
The formulation may be a liquid formulation.
The liquid preparation is injection, aerosol inhalation, spray or capsule.
The injection is solution type injection, suspension type injection or emulsion type injection.
In a fourth aspect, the present invention provides the use of a composition according to the first aspect.
Use of a composition according to the first aspect for the preparation of a medicament for immunomodulation, or for the treatment and/or prophylaxis of viral infectious diseases and tumours.
In some embodiments, the use of a composition according to the first aspect for the manufacture of a medicament for the treatment and/or prophylaxis of acute and chronic viral hepatitis, condyloma acuminatum, chronic cervicitis, cervical erosion, vaginitis, diseases caused by endopapilloma virus, diseases caused by herpes simplex virus, hairy cell leukemia, chronic granulocytic leukemia, lymphoma, aids-related kaposi's sarcoma, or malignant melanoma.
Advantageous effects
Compared with the prior art, the invention has at least one of the following beneficial technical effects:
(1) The invention is beneficial to improving the stability of the interferon composition by adding the L-ascorbic acid, avoiding the reduction of the specific activity of the interferon and the increase of related proteins under long-term conditions (-25+/-5 ℃) and acceleration conditions (5+/-3 ℃), and remarkably prolonging the effective period.
(2) The higher the purity of the L-ascorbic acid added, the more advantageous is the improvement of the specific activity of the interferon in the composition.
(3) The invention is beneficial to reducing the activity loss caused by adsorption and aggregation of the gas-liquid interface when the interferon is frozen by adding the surfactant, and can avoid the reduction of the specific activity of the interferon under long-term conditions (-25+/-5 ℃) and acceleration conditions (5+/-3 ℃).
(4) The L-ascorbic acid and the surfactant have synergistic technical effects, and the combination of the L-ascorbic acid and the surfactant can greatly improve the stability of the specific activity of the kana resistant interferon.
(5) The invention does not need to add propylene glycol, amino acid or human serum albumin as a protective agent, is beneficial to avoiding the irritation of the substances to the human body or the intolerance of the substances to the human body, is beneficial to avoiding the degradation of the substances in the placing process to bring new impurities, and is beneficial to improving the safety of medication; in addition, the invention does not need propylene glycol with hemolysis, glycine, alanine or human serum albumin with high storage difficulty, preparation difficulty and cost, and the invention has the advantages of less required materials, low cost, safety, green and environment-friendly property and is beneficial to industrialized production.
(6) The preparation method provided by the invention is simple to operate and is beneficial to industrial production.
Definition of terms:
in the invention, "room temperature" means the ambient temperature, which can be 20-30 ℃; in some embodiments, 22 ℃ to 28 ℃; in some embodiments, 24 ℃ to 26 ℃; in some embodiments, 25 ℃.
The term "interferon" may be a recombinant interferon or an interferon prepared by other methods, such as an extracted natural interferon, e.g., "human interferon alpha 2b" includes recombinant human interferon alpha 2b or human interferon alpha 2b prepared by other methods (e.g., extracted natural human interferon alpha 2 b).
In the context of the present invention, all numbers disclosed herein are approximations, whether or not the word "about" or "about" is used. Based on the numbers disclosed, there is a possibility that the values of each number may differ by less than + -10% or a reasonable difference as recognized by those skilled in the art, such as + -1%, + -2%, + -3%, + -4%, or + -5%.
The terms "optional," "optional," or "optionally" mean that the subsequently described event or circumstance may, but need not, occur. For example, "optional surfactant" means that the surfactant may or may not be present.
The term "weight percent" or "percent by weight" or "wt%" is defined as the weight of an individual component in a composition divided by the total weight of all components of the composition and then multiplied by 100.
The term "and/or" is understood to mean any one of the selectable items or a combination of any two or more of the selectable items.
As used herein, the term "treatment" refers to a clinical intervention intended to alter the natural course of a disease in an individual undergoing treatment. Desirable therapeutic effects include, but are not limited to, preventing occurrence or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, reducing the rate of disease progression, improving or moderating the disease state, and alleviating or improving prognosis.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
In this application, the "composition" may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. Generally, the compositions are prepared by uniformly and intimately bringing into association the active compound with liquid carriers, finely divided solid carriers or both.
Detailed Description
In order to better understand the technical solution of the present invention, some non-limiting examples are further disclosed below to further describe the present invention in detail.
The reagents used in the present invention are all commercially available or can be prepared by the methods described herein.
Comparative example 1: preparation of Interferon alpha 2b stock solution and stability investigation thereof
Construction of two different resistance engineering bacteria of ampicillin (ampicillin Lin Kangxing) and kana (kanamycin resistance) by E.coli to express interferon alpha 2b (respectively named as ampicillin resistant human interferon alpha 2b and kana resistant human interferon alpha 2 b) in a fermentation mannerThe engineering bacteria adopts the same culture medium and fermentation conditions, under the similar purification process and parameters, the final step of purifying and collecting the interferon alpha 2b stock solution contains the interferon with the concentration of 1mg/l-3mg/ml and the specific activity of 1.05X10 8 IU/mg-1.5×10 8 IU/mg. The two stock solutions contained: 1mg/L-3mg/ml interferon degree alpha 2b, disodium hydrogen phosphate-sodium dihydrogen phosphate buffer salt 10mmol/L. The two stock solutions were subjected to long term (-25.+ -. 5 ℃) and accelerated (5.+ -. 3 ℃) investigation and the final investigation results are shown in tables 1, 2, 3 and 4.
Table 1: stability examination result of ampicillin-resistant human interferon a2b stock solution under long-term condition (-25+ -5 ℃)
Table 2: results of examination of stability of Canada resistant human interferon alpha 2b stock solution under long-term conditions (-25.+ -. 5 ℃ C.)
Table 3: stability test results of acceleration condition (5+ -3 ℃) of ampicillin-resistant human interferon alpha 2b stock solution
Table 4: results of examination of stability of kana-resistant human interferon alpha 2b stock solution under acceleration conditions (5.+ -. 3 ℃ C.)
Conclusion: the two stock solutions of ampicillin and kana have no obvious difference in the relative protein, specific activity and the like in 0 month. However, the stability studies of the two stock solutions under the same conditions show a significant difference. Specifically, the kana-resistant stock solution is inferior to the ampicillin-resistant stock solution in terms of activity decrease and the growth degree of related proteins when the stock solution is examined for a long time. The difference of the resistance genes causes the cell wall structure morphology of the thalli and the purification process to bring corresponding change influence, and finally causes the stability difference of the stock solution.
Example 1: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 5.
Table 5: interferon alpha 2b composition formulation (based on total volume or total mass of the composition)
The preparation method comprises the following steps: preparing a buffer solution of disodium hydrogen phosphate and sodium dihydrogen phosphate according to the concentration shown in Table 5, dissolving L-ascorbic acid to a target concentration, performing ultrafiltration exchange of the collection solution purified in the last step of the kana-resistant human interferon a2b by using the buffer solution containing the L-ascorbic acid (the preparation method is the same as that of comparative example 1), performing filtration sterilization by using a 0.2 mu m filter membrane, subpackaging, and filling nitrogen into a headspace part to obtain the interferon alpha 2b composition.
Example 2: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 6.
Table 6: interferon alpha 2b composition formulation (based on total volume or total mass of the composition)
The preparation method comprises the following steps: preparing a buffer solution of disodium hydrogen phosphate and sodium dihydrogen phosphate according to the concentration shown in Table 6, dissolving L-ascorbic acid to a target concentration, performing ultrafiltration exchange of the collection solution purified in the last step of the kana-resistant human interferon alpha 2b by using the buffer solution containing the L-ascorbic acid (the preparation method is the same as that of comparative example 1), performing filtration sterilization by using a 0.2 mu m filter membrane, subpackaging, and filling nitrogen into a headspace part to obtain the interferon alpha 2b composition.
Example 3: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 7.
Table 7: interferon alpha 2b composition formulation (based on total volume or total mass of the composition)
The preparation method comprises the following steps: preparing a buffer solution of disodium hydrogen phosphate and sodium dihydrogen phosphate according to the concentration shown in Table 7, dissolving L-ascorbic acid and Tween 80 to a target concentration, carrying out ultrafiltration exchange of the collection solution purified in the last step of the kana-resistant human interferon alpha 2b by using the buffer solution containing the L-ascorbic acid and the Tween 80 (the preparation method is the same as that of comparative example 1), finally filtering and sterilizing by using a 0.2 mu m filter membrane, subpackaging, and filling nitrogen into a headspace part to obtain the interferon alpha 2b composition.
Example 4: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 8.
Table 8: interferon alpha 2b composition formulation (based on total volume or total mass of the composition)
The preparation method comprises the following steps: preparing a buffer solution of disodium hydrogen phosphate and sodium dihydrogen phosphate according to the concentration shown in Table 8, dissolving L-ascorbic acid and Tween 80 to a target concentration, carrying out ultrafiltration exchange of the collection solution purified in the last step of the kana-resistant human interferon alpha 2b by using the buffer solution containing the L-ascorbic acid and the Tween 80 (the preparation method is the same as that of comparative example 1), finally filtering and sterilizing by using a 0.2 mu m filter membrane, subpackaging, and filling nitrogen into a headspace part to obtain the interferon alpha 2b composition.
Example 5: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 9.
Table 9: interferon alpha 2b composition formulation (based on total volume or total mass of the composition)
The preparation method comprises the following steps: preparing buffer solution of citric acid and sodium citrate according to the concentration shown in Table 9, dissolving L-ascorbic acid and Tween 80 to target concentration, carrying out ultrafiltration liquid exchange on the collection liquid purified in the last step of the kana-resistant human interferon alpha 2b by using the buffer solution containing the L-ascorbic acid and the Tween 80 (the preparation method is the same as that of comparative example 1), finally filtering and sterilizing by using a 0.2 mu m filter membrane, sub-packaging, and filling nitrogen into a part of the headspace to obtain the interferon alpha 2b composition.
Example 6: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 10.
Table 10: interferon alpha 2b composition prescription
The preparation method comprises the following steps: preparing a buffer solution of acetic acid and sodium acetate according to the concentration shown in Table 10, dissolving L-ascorbic acid and Tween 80 to a target concentration, performing ultrafiltration exchange of the collection solution purified in the last step of the kana-resistant human interferon alpha 2b by using the buffer solution containing the L-ascorbic acid and the Tween 80 (the preparation method is the same as that of comparative example 1), performing filtration sterilization by using a 0.2 mu m filter membrane, sub-packaging, and filling part of the headspace with nitrogen gas to obtain the interferon alpha 2b composition.
Example 7: preparation of Interferon alpha 2b compositions
Prescription: as shown in table 11.
Table 11: interferon alpha 2b composition prescription
The preparation method comprises the following steps: preparing a buffer solution of disodium hydrogen phosphate and sodium dihydrogen phosphate according to the concentration shown in table 11, dissolving Tween 80 to a target concentration, performing ultrafiltration exchange on the collected solution purified in the last step of the kana-resistant human interferon alpha 2b by using the buffer solution containing Tween 80 (the preparation method is the same as that of comparative example 1), performing filtration sterilization by using a 0.2 mu m filter membrane, sub-packaging, and filling nitrogen into a part of the headspace to obtain the interferon alpha 2b composition.
Example 8: stability detection
The interferon alpha 2b compositions obtained in examples 1 to 7 were examined under accelerated conditions (5.+ -. 3 ℃ C.) and the final examination results are shown in Table 12.
Table 12: stability test results under acceleration conditions (5.+ -. 3 ℃ C.)
Analysis of results: from the results in Table 11 and tables 1 to 4, it can be seen that:
(1) From the results of example 1, example 2 and tables 1 to 4, it is understood that the present invention is advantageous to improve the specific activity of the Canada resistant interferon under accelerated conditions and the stability of the relevant proteins by adding an appropriate amount of L-ascorbic acid, and in particular, the specific activity of the Canada resistant interferon under accelerated conditions and the stability of the relevant proteins can be improved significantly by adding an appropriate amount of high-purity L-ascorbic acid, and the higher the purity of L-ascorbic acid is, the better the specific activity of the Canada resistant interferon under accelerated conditions and the stability of the relevant proteins are.
(2) From the results of example 2 and example 3, it was found that the addition of the surfactant, on the basis of L-ascorbic acid, can improve the stability of the specific activity of the interferon against kana and can improve the initial specific activity 0 days after the preparation.
(3) From the results of example 3, example 4 and example 6, it is understood that an appropriate increase in the content of L-ascorbic acid is advantageous in improving the stability of the kana-resistant interferon.
(4) From the results of example 2, example 4 and example 5, it is understood that if example 5 is not adjusted to pH 4.5 but to pH 7.0, the change in specific activity of the accelerating condition-dependent interferon should be theoretically between that of example 2 and example 4, but that of example 5, pH is adjusted to pH 4.5, and that of example 2 and example 4, the change in specific activity of the accelerating condition-dependent interferon is much better than that of example 5, indicating that the preferred pH range of the present invention is 6.0-7.0.
(5) The L-ascorbic acid and the surfactant have synergistic technical effects, and the combination of the L-ascorbic acid and the surfactant can greatly improve the stability of the specific activity of the kana resistant interferon.
In combination, the L-ascorbic acid has outstanding effect on the stabilization of interferon, can comprehensively solve the influence caused by the upstream process, prolongs the storage period of stock solution, and saves the optimization time cost of the upstream process. In addition, through researches, the stability of the interferon stock solution is further improved by collocating the components of the stock solution composition, such as adding the surfactant, and the preservation time of the stock solution is remarkably prolonged.
While the methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations and combinations of the methods and applications described herein can be made and applied within the spirit and scope of the invention. Those skilled in the art can, with the benefit of this disclosure, suitably modify the process parameters to achieve this. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included within the present invention.
Claims (2)
1. A composition comprising human interferon alpha 2b, L-ascorbic acid, phosphate buffer salt, and tween 80;
the purity of the L-ascorbic acid is more than or equal to 98%;
the L-ascorbic acid is present in an amount of 5mmol/L based on the total volume of the composition;
the phosphate buffer salt is present at a concentration of 10mmol/L based on the total volume of the composition;
the tween 80 content was 0.05wt%, based on the total mass of the composition;
the interferon is present in an amount of 1.0mg/mL based on the total volume of the composition;
the pH of the composition is 6.0-7.0.
2. The composition of claim 1, wherein the composition does not comprise propylene glycol, glycine, alanine, or human serum albumin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111251289.0A CN113797317B (en) | 2021-10-26 | 2021-10-26 | Composition, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111251289.0A CN113797317B (en) | 2021-10-26 | 2021-10-26 | Composition, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113797317A CN113797317A (en) | 2021-12-17 |
CN113797317B true CN113797317B (en) | 2024-01-09 |
Family
ID=78938038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111251289.0A Active CN113797317B (en) | 2021-10-26 | 2021-10-26 | Composition, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113797317B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115531315B (en) * | 2022-12-05 | 2023-04-07 | 上海惠盾因泰生物科技有限公司 | Recombinant human interferon lambda 1 nasal spray and application thereof |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503828A (en) * | 1992-02-10 | 1996-04-02 | Interferon Sciences, Inc. | Alpha interferon composition and method for its production from human peripheral blood leukocytes |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
RU2218934C2 (en) * | 2001-04-04 | 2003-12-20 | Государственный научно-исследовательский институт особо чистых биопрепаратов | Interferon preparation |
CN1660414A (en) * | 2005-01-17 | 2005-08-31 | 哈药集团生物工程有限公司 | Stable preparation of interferon |
CN101234193A (en) * | 2008-02-26 | 2008-08-06 | 上海欣百诺生物科技有限公司 | Stable water solution containing recombination human serum albumin fusion interferon |
CN101954067A (en) * | 2010-08-25 | 2011-01-26 | 齐鲁制药有限公司 | Aqueous solution of recombinant human serum albumin-interferon alpha fusion protein and preparation method thereof |
WO2012015325A1 (en) * | 2010-07-27 | 2012-02-02 | Malinovskaya Valentina Vasilievna | Stabilized immune correction drug viferon-forte for the treatment of infectious inflammatory diseases |
RU2011103923A (en) * | 2011-02-04 | 2012-08-10 | Закрытое акционерное общество "Мосагроген" (ЗАО "Мосагроген") (RU) | COMPOSITION FOR VETERINARY MEDICINE CONTAINING human recombinant interferon alfa-2B, tocopherol acetate and ascorbic acid, a drug for veterinary MULTIFERON® AT ITS BASE AND APPLICATION OF DRUG MULTIFERON® as an antiviral and immunomodulating agents in the vaccination schedule of young farm animals |
CN103432569A (en) * | 2010-08-25 | 2013-12-11 | 齐鲁制药有限公司 | Recombinant human serum albumin-interferon alpha fusion protein water solution and preparation method thereof |
CN103432573A (en) * | 2010-08-25 | 2013-12-11 | 齐鲁制药有限公司 | Recombinant human serum albumin-interferon alpha fusion protein water solution and preparation method thereof |
CN112043685A (en) * | 2020-09-18 | 2020-12-08 | 深圳科兴药业有限公司 | Recombinant human interferon alpha 1b mutant inhalation solution and preparation method thereof |
CN114470167A (en) * | 2020-11-13 | 2022-05-13 | 深圳赛保尔生物药业有限公司 | Interferon eye drops and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1175901C (en) * | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | Stable water solution of interferon |
US20030138403A1 (en) * | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
RS52218B (en) * | 2003-12-11 | 2012-10-31 | Ares Trading S.A. | Stabilized interferon liquid formulations |
US8048848B2 (en) * | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US20100297081A1 (en) * | 2007-12-18 | 2010-11-25 | Huang Yanshan | Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein |
-
2021
- 2021-10-26 CN CN202111251289.0A patent/CN113797317B/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503828A (en) * | 1992-02-10 | 1996-04-02 | Interferon Sciences, Inc. | Alpha interferon composition and method for its production from human peripheral blood leukocytes |
RU2218934C2 (en) * | 2001-04-04 | 2003-12-20 | Государственный научно-исследовательский институт особо чистых биопрепаратов | Interferon preparation |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
CN1660414A (en) * | 2005-01-17 | 2005-08-31 | 哈药集团生物工程有限公司 | Stable preparation of interferon |
CN101234193A (en) * | 2008-02-26 | 2008-08-06 | 上海欣百诺生物科技有限公司 | Stable water solution containing recombination human serum albumin fusion interferon |
WO2012015325A1 (en) * | 2010-07-27 | 2012-02-02 | Malinovskaya Valentina Vasilievna | Stabilized immune correction drug viferon-forte for the treatment of infectious inflammatory diseases |
CN101954067A (en) * | 2010-08-25 | 2011-01-26 | 齐鲁制药有限公司 | Aqueous solution of recombinant human serum albumin-interferon alpha fusion protein and preparation method thereof |
CN103432569A (en) * | 2010-08-25 | 2013-12-11 | 齐鲁制药有限公司 | Recombinant human serum albumin-interferon alpha fusion protein water solution and preparation method thereof |
CN103432573A (en) * | 2010-08-25 | 2013-12-11 | 齐鲁制药有限公司 | Recombinant human serum albumin-interferon alpha fusion protein water solution and preparation method thereof |
RU2011103923A (en) * | 2011-02-04 | 2012-08-10 | Закрытое акционерное общество "Мосагроген" (ЗАО "Мосагроген") (RU) | COMPOSITION FOR VETERINARY MEDICINE CONTAINING human recombinant interferon alfa-2B, tocopherol acetate and ascorbic acid, a drug for veterinary MULTIFERON® AT ITS BASE AND APPLICATION OF DRUG MULTIFERON® as an antiviral and immunomodulating agents in the vaccination schedule of young farm animals |
CN112043685A (en) * | 2020-09-18 | 2020-12-08 | 深圳科兴药业有限公司 | Recombinant human interferon alpha 1b mutant inhalation solution and preparation method thereof |
CN114470167A (en) * | 2020-11-13 | 2022-05-13 | 深圳赛保尔生物药业有限公司 | Interferon eye drops and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113797317A (en) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2888969B2 (en) | Stabilized hydrophobic protein preparation | |
EP1712223B1 (en) | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer | |
CZ110497A3 (en) | Stable water soluble preparation containing alpha interferon | |
EP0374257B1 (en) | STABLE INTERFERON $g(b) COMPOSITION | |
CN113797317B (en) | Composition, and preparation method and application thereof | |
JP2009528327A (en) | G-CSF liquid formulation | |
EP0089245A2 (en) | A stable interferon beta composition and a method of stabilizing interferon beta | |
WO2002080958A1 (en) | Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor | |
US4483849A (en) | Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product | |
CN114470167A (en) | Interferon eye drops and preparation method thereof | |
US20030170207A1 (en) | Stable aqua formulation of interferon, the preparation method and the uses thereof | |
US9593151B2 (en) | Use of fusion protein | |
KR20090118030A (en) | Hgf preparation | |
CN113797318B (en) | Interferon composition and preparation method and application thereof | |
EP2911685A2 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
US20040101573A1 (en) | Injectable composition for cancer treatment | |
CN111375057B (en) | Pharmaceutical formulation comprising anti-Her 2 monoclonal antibody | |
CN1802171A (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
RU2140285C1 (en) | Antiviral agent - nasal drops "grippferon" | |
EP1200115B9 (en) | Multi-dose erythropoietin formulations | |
JPH10510841A (en) | Thrombopoietin composition | |
CN113797171A (en) | Pegylated recombinant human granulocyte colony stimulating factor freeze-dried preparation | |
RU2380405C2 (en) | Method for making recombinant human alpha 16-interferon and pharmaceutical composition for treating viral diseases based on recombinant human alpha 16-interferon | |
RU2255729C1 (en) | Alpha-interferon preparation in the form of stable aqueous solution for injections | |
CN103182073A (en) | Pharmaceutical injection of recombinant human interferon alpha-CTP fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |